Thursday, October 15, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 13, 2026

10 Information Technology Stocks Whale Activity In Today's Session

View original at finance.yahoo.com
10 Information Technology Stocks Whale Activity In Today's Session This whale alert can help traders discover the next big trading opportunities…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Abnormal amounts of options trading activity can push option prices to hyperbolic or underperforming levels relative to their intrinsic value.

    60% confidence

  • NVDA whale call trade is bullish with 250 contracts at $225 strike expiring same day, priced at $195 per contract totaling $48.7K, against 32,510 open interest and 297,517 session volume.

    60% confidence

  • Whale options activity can help traders discover the next big trading opportunities by revealing where large-money entities are placing directional bets.

    60% confidence

  • MU whale call trade is bearish with 10 contracts at $800 strike at $2,940 per contract totaling $29.4K, against 13,279 open interest and 22,748 session volume.

    60% confidence

  • AAPL whale call sweep is neutral sentiment with 110 contracts at $300 strike, required 9 separate fills, at $286 per contract totaling $31.5K, against 81,123 open interest and 114,691 session volume.

    60% confidence

Data points we hold from this source

Dell Technologies · options volume1800 contracts
Dell Technologies · options open interest1900 contracts
HP Inc. · options volume1000 contracts
HP Inc. · options open interest1700 contracts
Taiwan Semiconductor Manufacturing Company · options open interest7000 contracts
Taiwan Semiconductor Manufacturing Company · options volume2800 contracts
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com